A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03099876|
Recruitment Status : Unknown
Verified April 2017 by IL-YANG RA, Il-Yang Pharm. Co., Ltd..
Recruitment status was: Recruiting
First Posted : April 4, 2017
Last Update Posted : April 7, 2017
Il-Yang Pharm. Co., Ltd.
Information provided by (Responsible Party):
IL-YANG RA, Il-Yang Pharm. Co., Ltd.
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||December 1, 2017|
|Estimated Study Completion Date :||December 1, 2018|